SW · BAYN.SW
Bayer AG
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Leverkusen 51368
- Website
- bayer.com
Price · as of 2024-12-31
$33.97
Market cap 37.63B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $49.29 | $45.56 | $0.00 | $9.00 | $29.70 |
| 2011 | $43.97 | $39.42 | $4.66 | $14.60 | $33.90 |
| 2012 | $45.25 | $46.21 | $2.58 | $1.00 | $45.80 |
| 2013 | $46.77 | $46.45 | $0.10 | $3.60 | $32.80 |
| 2014 | $125.84 | $83.24 | $1.99 | $0.00 | $50.80 |
| 2015 | $91.79 | $77.25 | $0.25 | $0.80 | $80.50 |
| 2016 | $98.08 | $86.86 | $0.67 | $5.40 | $46.20 |
| 2017 | $97.39 | $85.58 | $3.87 | $24.90 | $0.00 |
| 2018 | $69.63 | $78.34 | $1.24 | $0.00 | $36.00 |
| 2019 | $99.19 | $95.99 | $0.00 | $0.00 | $41.00 |
| 2020 | $196.02 | $124.14 | $10.56 | $0.00 | $0.00 |
| 2021 | $198.00 | $126.68 | $12.77 | $0.00 | $13.60 |
| 2022 | $0.00 | $89.50 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Bayer AG's (BAYN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $33.97
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
- CEO
- William N. Anderson
- Employees
- 96.93K
- Beta
- 0.97
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $33.97) − 1 = — (DCF, example).